Preliminary trials demonstrate that Retatrutide – a dual stimulator of GLP-1 and GIP receptors – presents a significant advance in weight management therapies. Unlike existing treatments , the peptide appears to affect food intake and energy expenditure through multiple routes. Despite additional investigation is essential, early results raise